{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:59:47Z","timestamp":1792159187674,"version":"4.4.0"},"reference-count":194,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100023945","name":"Department of Radiation Oncology, School of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","award":["Startup funds"],"award-info":[{"award-number":["Startup funds"]}],"id":[{"id":"10.13039\/100023945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35 GM136352"],"award-info":[{"award-number":["R35 GM136352"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Institutional Research Grant IRG-24-1299098-64-IRG"],"award-info":[{"award-number":["Institutional Research Grant IRG-24-1299098-64-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The complement system, a key component of the immune response, plays a dual role in cancer, influencing both tumor suppression and progression. Its three activation pathways (classical, alternative, and lectin) initiate immune processes, including opsonization and cell lysis. Within the tumor microenvironment, however, complement activation can paradoxically support immune-mediated tumor control or contribute to immune evasion and tumor growth. Therapeutic interventions such as radiation and certain chemotherapies can trigger complement activation by inducing immunogenic cell death and the release of damage-associated molecular patterns. This activation leads to the generation of anaphylatoxins C3a and C5a, which recruit immune cells to the tumor site and promote antitumor immunity. However, these same fragments may also foster an immunosuppressive microenvironment by attracting regulatory T cells and myeloid-derived suppressor cells, thereby limiting the efficacy of immunotherapies. Additionally, tumor cells often upregulate membrane complement regulatory proteins, including CD46, CD55, and CD59, to escape complement-mediated cytotoxicity and immune surveillance. Recent insights indicate that the complement system is a critical barrier to effective immunotherapy. Complement inhibition, particularly by targeting C3a receptor and C5a receptor 1, has been shown to synergize with immune checkpoint inhibitors (eg, anti-programmed cell death protein-1\/programmed death-ligand 1), reversing complement-driven immunosuppression and enhancing T cell\u2013mediated tumor rejection. Combining complement blockade with proimmunogenic therapies such as radiation or chemotherapy may further amplify these effects by uncoupling therapy-induced complement activation from its immunosuppressive consequences. Thus, the interplay between complement activation and cancer therapeutics presents a promising avenue for treatment innovations. Strategic modulation of complement, whether through genetic, pharmacologic, or antibody-based approaches, could sensitize tumors to immunotherapy and help overcome resistance mechanisms. Continued investigation into this crosstalk will be essential for designing effective combination strategies that maximize antitumor immunity while minimizing immune escape.<\/jats:p>","DOI":"10.1136\/jitc-2025-013290","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:30:26Z","timestamp":1773297026000},"page":"e013290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Complement system in cancer: friend or foe of immunotherapy"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04314089","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03665129","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04812535","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04947033","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04919629","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Harendra Kumar","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5236-6132","authenticated-orcid":false,"given":"Sai","family":"Prem","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Kathryn","family":"Liszewski","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-7974","authenticated-orcid":false,"given":"Abhay Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"},{"name":"MilliporeSigma St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-1487","authenticated-orcid":false,"given":"Vaishali","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA"},{"name":"Siteman Cancer Center, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026031123301574000_14.3.e013290.1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0891"},{"key":"2026031123301574000_14.3.e013290.2","doi-asserted-by":"crossref","first-page":"810993","DOI":"10.3389\/fimmu.2022.810993","article-title":"Complement System: An Immunotherapy Target in Colorectal Cancer","volume":"13","author":"Talaat","year":"2022","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.03.009"},{"key":"2026031123301574000_14.3.e013290.4","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.97"},{"key":"2026031123301574000_14.3.e013290.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.11.008"},{"key":"2026031123301574000_14.3.e013290.6","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.smim.2025.101951","article-title":"Interplay between the complement system and other immune pathways in the tumor microenvironment","volume":"78","author":"Garlanda","year":"2025","journal-title":"Semin Immunol"},{"key":"2026031123301574000_14.3.e013290.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0435"},{"key":"2026031123301574000_14.3.e013290.8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.celrep.2014.06.051","article-title":"Complement-dependent modulation of antitumor immunity following radiation therapy","volume":"8","author":"Elvington","year":"2014","journal-title":"Cell Rep"},{"key":"2026031123301574000_14.3.e013290.9","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12672","article-title":"Complement system\u2019s role in cancer and its therapeutic potential in ovarian cancer","volume":"88","author":"Bareke","year":"2018","journal-title":"Scand J Immunol"},{"key":"2026031123301574000_14.3.e013290.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00669","article-title":"Complement in Metastasis: A Comp in the Camp","volume":"10","author":"Ajona","year":"2019","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.11","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3892\/ol.2017.6555","article-title":"CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"2026031123301574000_14.3.e013290.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.018"},{"key":"2026031123301574000_14.3.e013290.13","doi-asserted-by":"crossref","unstructured":"Arbore G , West EE , Spolski R . T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 2016;352. doi:10.1126\/science.aad1210","DOI":"10.1126\/science.aad1210"},{"key":"2026031123301574000_14.3.e013290.14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf2489","article-title":"Mitochondrial C5aR1 activity in macrophages controls IL-1\u03b2 production underlying sterile inflammation","volume":"6","author":"Niyonzima","year":"2021","journal-title":"Sci Immunol"},{"key":"2026031123301574000_14.3.e013290.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0532"},{"key":"2026031123301574000_14.3.e013290.16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0787"},{"key":"2026031123301574000_14.3.e013290.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110851"},{"key":"2026031123301574000_14.3.e013290.18","unstructured":"Garavito Rodr\u00edguez \u00c9 . The Complement System. El Rosario University Press, 2013."},{"key":"2026031123301574000_14.3.e013290.19","doi-asserted-by":"crossref","unstructured":"Atkinson JP , Clos TW , Mold C , et al . 21 - the human complement system: basic concepts and clinical relevance. In: Rich RR , Fleisher TA , Shearer WT , et al , eds. Clinical Immunology. 5th edn. London: Elsevier, 2019: 299\u2013317.","DOI":"10.1016\/B978-0-7020-6896-6.00021-1"},{"key":"2026031123301574000_14.3.e013290.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-024-03273-7","article-title":"Complement proteins and complement regulatory proteins are associated with age-related macular degeneration stage and treatment response","volume":"21","author":"Thomsen","year":"2024","journal-title":"J Neuroinflammation"},{"key":"2026031123301574000_14.3.e013290.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.2.628"},{"key":"2026031123301574000_14.3.e013290.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.07.016"},{"key":"2026031123301574000_14.3.e013290.23","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90155-4"},{"key":"2026031123301574000_14.3.e013290.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1102167108"},{"key":"2026031123301574000_14.3.e013290.25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.148.4.1044"},{"key":"2026031123301574000_14.3.e013290.26","doi-asserted-by":"publisher","DOI":"10.1038\/nri2620"},{"key":"2026031123301574000_14.3.e013290.27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.547083"},{"key":"2026031123301574000_14.3.e013290.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03135.x"},{"key":"2026031123301574000_14.3.e013290.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2010.07373.x"},{"key":"2026031123301574000_14.3.e013290.30","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.4049\/jimmunol.1200834","article-title":"C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay","volume":"189","author":"Reis","year":"2012","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2328"},{"key":"2026031123301574000_14.3.e013290.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2024.02.003","article-title":"Elevated expression of complement factor I in lung cancer cells associates with shorter survival\u2013Potentially via non-canonical mechanism","volume":"269","author":"Felberg","year":"2024","journal-title":"Transl Res"},{"key":"2026031123301574000_14.3.e013290.33","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.165.7.3999","article-title":"Cooperation Between Decay-Accelerating Factor and Membrane Cofactor Protein in Protecting Cells from Autologous Complement Attack","volume":"165","author":"Brodbeck","year":"2000","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.34","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2001.1800110.x"},{"key":"2026031123301574000_14.3.e013290.35","doi-asserted-by":"crossref","unstructured":"Lublin DM , Atkinson JP , eds. Decay-Accelerating Factor and Membrane Cofactor Protein. The Third Component of Complement. Berlin: Heidelberg: Springer Berlin Heidelberg, 1990.","DOI":"10.1007\/978-3-642-74977-3_7"},{"key":"2026031123301574000_14.3.e013290.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.70"},{"key":"2026031123301574000_14.3.e013290.37","doi-asserted-by":"crossref","unstructured":"Elvington M , Liszewski MK , Atkinson JP . CD46 and Oncologic Interactions: Friendly Fire against Cancer. Antibodies (Basel) 2020;9.","DOI":"10.3390\/antib9040059"},{"key":"2026031123301574000_14.3.e013290.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01074","article-title":"The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy","volume":"10","author":"Geller","year":"2019","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.39","doi-asserted-by":"crossref","unstructured":"Liszewski MK , Atkinson JP . The multiverse of CD46 and oncologic interactions. J Clin Invest 2025;135.","DOI":"10.1172\/JCI188355"},{"key":"2026031123301574000_14.3.e013290.40","doi-asserted-by":"crossref","unstructured":"Saxena R , Gottlin EB , Campa MJ , et al . Complement factor H: a novel innate immune checkpoint in cancer immunotherapy. Front Cell Dev Biol 2024;12. doi:10.3389\/fcell.2024.1302490","DOI":"10.3389\/fcell.2024.1302490"},{"key":"2026031123301574000_14.3.e013290.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01132-2"},{"key":"2026031123301574000_14.3.e013290.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-019-1027-3","article-title":"Role of the complement system in the tumor microenvironment","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2026031123301574000_14.3.e013290.43","doi-asserted-by":"crossref","unstructured":"Sonderegger SE , Manzanero S , Woodruff TM , et al . CHAPTER 3 - the role of the complement system in cancer etiology and management. In: Niederhuber JE , ed. Clinical Immuno-Oncology. New Delhi: Elsevier, 2024: 41\u201360.","DOI":"10.1016\/B978-0-323-87763-3.00012-5"},{"key":"2026031123301574000_14.3.e013290.44","article-title":"Targeting C3a and C5a Signaling-A Game Changer for Cancer Therapy?","volume":"14","author":"Hudgins","year":"2025","journal-title":"Biology (Basel)"},{"key":"2026031123301574000_14.3.e013290.45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","article-title":"Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity","volume":"32","author":"Luan","year":"2024","journal-title":"Mol Ther"},{"key":"2026031123301574000_14.3.e013290.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0157"},{"key":"2026031123301574000_14.3.e013290.47","doi-asserted-by":"crossref","unstructured":"O\u2019Brien RM , Cannon A , Reynolds JV , et al . Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13061209"},{"key":"2026031123301574000_14.3.e013290.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0210-0"},{"key":"2026031123301574000_14.3.e013290.49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10346","article-title":"C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation","volume":"7","author":"Bulla","year":"2016","journal-title":"Nat Commun"},{"key":"2026031123301574000_14.3.e013290.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801015105"},{"key":"2026031123301574000_14.3.e013290.51","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3892\/or.2014.3341","article-title":"Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness","volume":"32","author":"Nitta","year":"2014","journal-title":"Oncol Rep"},{"key":"2026031123301574000_14.3.e013290.52","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.3389\/fimmu.2018.02742","article-title":"MASP-1 and MASP-2 Serum Levels Are Associated With Worse Prognostic in Cervical Cancer Progression","volume":"9","author":"Maestri","year":"2018","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.53","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00262-014-1579-y","article-title":"Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours","volume":"63","author":"Swierzko","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2026031123301574000_14.3.e013290.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1272"},{"key":"2026031123301574000_14.3.e013290.55","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00262-013-1445-3","article-title":"Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours","volume":"62","author":"Szala","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2026031123301574000_14.3.e013290.56","doi-asserted-by":"crossref","DOI":"10.7754\/Clin.Lab.2020.200249","article-title":"The Clinical Significance of Serum MASP-2 and IDH1 in the Early Diagnosis of Non-Small Cell Lung Cancer","volume":"66","author":"Chen","year":"2020","journal-title":"Clin Lab"},{"key":"2026031123301574000_14.3.e013290.57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0321"},{"key":"2026031123301574000_14.3.e013290.58","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23690","article-title":"Complement C4d-specific antibodies for the diagnosis of lung cancer","volume":"9","author":"Ajona","year":"2017","journal-title":"Oncotarget"},{"key":"2026031123301574000_14.3.e013290.59","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0467"},{"key":"2026031123301574000_14.3.e013290.60","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.0300-9475.2004.01423bn.x","article-title":"Preoperative Mannan\u2010Binding Lectin Pathway and Prognosis in Colorectal Cancer","volume":"59","author":"Ytting","year":"2004","journal-title":"Scand J Immunol"},{"key":"2026031123301574000_14.3.e013290.61","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201000127"},{"key":"2026031123301574000_14.3.e013290.62","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/odi.12363","article-title":"Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma","volume":"21","author":"Ajona","year":"2015","journal-title":"Oral Dis"},{"key":"2026031123301574000_14.3.e013290.63","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgl198"},{"key":"2026031123301574000_14.3.e013290.64","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.21037\/tcr-20-1990","article-title":"Review of non-invasive urinary biomarkers in bladder cancer","volume":"9","author":"Lee","year":"2020","journal-title":"Transl Cancer Res TCR"},{"key":"2026031123301574000_14.3.e013290.65","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.295"},{"key":"2026031123301574000_14.3.e013290.66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.700711","article-title":"Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"2026031123301574000_14.3.e013290.67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061117","article-title":"Mannose-binding lectin 2 gene and risk of adult glioma","volume":"8","author":"Michaud","year":"2013","journal-title":"PLoS One"},{"key":"2026031123301574000_14.3.e013290.68","doi-asserted-by":"crossref","first-page":"101921","DOI":"10.1016\/j.smim.2024.101921","article-title":"The complement system in clinical oncology: Applications, limitations and challenges","volume":"77","author":"Ajona","year":"2025","journal-title":"Semin Immunol"},{"key":"2026031123301574000_14.3.e013290.69","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655"},{"key":"2026031123301574000_14.3.e013290.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.12.027"},{"key":"2026031123301574000_14.3.e013290.71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yexcr.2018.03.009","article-title":"Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer","volume":"366","author":"Piao","year":"2018","journal-title":"Exp Cell Res"},{"key":"2026031123301574000_14.3.e013290.72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13108"},{"key":"2026031123301574000_14.3.e013290.73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246939","article-title":"Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues","volume":"16","author":"N\u00fcrge","year":"2021","journal-title":"PLoS ONE"},{"key":"2026031123301574000_14.3.e013290.74","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1412"},{"key":"2026031123301574000_14.3.e013290.75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s43018-021-00173-0","article-title":"Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression","volume":"2","author":"Magrini","year":"2021","journal-title":"Nat Cancer"},{"key":"2026031123301574000_14.3.e013290.76","doi-asserted-by":"publisher","DOI":"10.1038\/nm814"},{"key":"2026031123301574000_14.3.e013290.77","doi-asserted-by":"crossref","unstructured":"Herbert A . Complement controls the immune synapse and tumors control complement. J Immunother Cancer 2020;8.","DOI":"10.1136\/jitc-2020-001712"},{"key":"2026031123301574000_14.3.e013290.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.04.001"},{"key":"2026031123301574000_14.3.e013290.79","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt205"},{"key":"2026031123301574000_14.3.e013290.80","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01579-x"},{"key":"2026031123301574000_14.3.e013290.81","first-page":"1039","article-title":"Persistent complement activation on tumor cells in breast cancer","volume":"140","author":"Niculescu","year":"1992","journal-title":"Am J Pathol"},{"key":"2026031123301574000_14.3.e013290.82","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000218"},{"key":"2026031123301574000_14.3.e013290.83","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2808::AID-CNCR2820731125>3.0.CO;2-P"},{"key":"2026031123301574000_14.3.e013290.84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00752","article-title":"Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention","volume":"10","author":"Fishelson","year":"2019","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.002"},{"key":"2026031123301574000_14.3.e013290.86","doi-asserted-by":"crossref","unstructured":"Platt JL , Zhao C , Chicca J , et al . Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells. Proc Natl Acad Sci USA 2024;121.","DOI":"10.1073\/pnas.2405824121"},{"key":"2026031123301574000_14.3.e013290.87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family \u2013 an update","volume":"Volume","author":"S\u00e1ndor","year":"2024","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.88","doi-asserted-by":"publisher","DOI":"10.3390\/biom2010046"},{"key":"2026031123301574000_14.3.e013290.89","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1731135","article-title":"Complement inhibitor factor H expressed by breast cancer cells differentiates CD14(+) human monocytes into immunosuppressive macrophages","volume":"9","author":"Smolag","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026031123301574000_14.3.e013290.90","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/2326-6066.CIR-23-1092","article-title":"Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment","volume":"13","author":"Smolag","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026031123301574000_14.3.e013290.91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-025-08713-9","article-title":"Granzyme K activates the entire complement cascade","volume":"641","author":"Donado","year":"2025","journal-title":"Nature New Biol"},{"key":"2026031123301574000_14.3.e013290.92","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-024-08395-9","article-title":"GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases","volume":"638","author":"Lan","year":"2025","journal-title":"Nature New Biol"},{"key":"2026031123301574000_14.3.e013290.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.015"},{"key":"2026031123301574000_14.3.e013290.94","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33598-x","article-title":"Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer","volume":"13","author":"Monteran","year":"2022","journal-title":"Nat Commun"},{"key":"2026031123301574000_14.3.e013290.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.09.003"},{"key":"2026031123301574000_14.3.e013290.96","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41416-025-03185-0","article-title":"Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma","volume":"133","author":"Eto","year":"2025","journal-title":"Br J Cancer"},{"key":"2026031123301574000_14.3.e013290.97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00420","article-title":"The High Prevalence of Functional Complement Defects Induced by Chemotherapy","volume":"7","author":"Keizer","year":"2016","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170438"},{"key":"2026031123301574000_14.3.e013290.99","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026031123301574000_14.3.e013290.100","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of Local Radiation Therapy in Cancer Immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026031123301574000_14.3.e013290.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2026031123301574000_14.3.e013290.102","doi-asserted-by":"crossref","first-page":"106761","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026031123301574000_14.3.e013290.103","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026031123301574000_14.3.e013290.104","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-23-0399","article-title":"The Yin Yang of Complement and Cancer","volume":"11","author":"Meri","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026031123301574000_14.3.e013290.105","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"2026031123301574000_14.3.e013290.106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41419-024-06500-4","article-title":"Blockade of C5aR1 resets M1 via gut microbiota-mediated PFKM stabilization in a TLR5-dependent manner","volume":"15","author":"Zhao","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026031123301574000_14.3.e013290.107","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168277","article-title":"Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1","volume":"133","author":"Beach","year":"2023","journal-title":"J Clin Invest"},{"key":"2026031123301574000_14.3.e013290.108","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/cancers17142383","article-title":"Radiotherapy Upregulates the Expression of Membrane-Bound Negative Complement Regulator Proteins on Tumor Cells and Limits Complement-Mediated Tumor Cell Lysis","volume":"17","author":"Liang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026031123301574000_14.3.e013290.109","doi-asserted-by":"crossref","first-page":"217253","DOI":"10.1016\/j.canlet.2024.217253","article-title":"Complement is increased in treatment resistant rectal cancer and modulates radioresistance","volume":"604","author":"O\u2019Brien","year":"2024","journal-title":"Cancer Lett"},{"key":"2026031123301574000_14.3.e013290.110","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10583-1","article-title":"Combined anti-C1-INH and radiotherapy against glioblastoma","volume":"23","author":"Liljedahl","year":"2023","journal-title":"BMC Cancer"},{"key":"2026031123301574000_14.3.e013290.111","doi-asserted-by":"crossref","first-page":"37421","DOI":"10.18632\/oncotarget.26456","article-title":"Anti-C1-inactivator treatment of glioblastoma","volume":"9","author":"F\u00f6rnvik","year":"2018","journal-title":"Oncotarget"},{"key":"2026031123301574000_14.3.e013290.112","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/2767-9764.CRC-22-0069","article-title":"The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer","volume":"2","author":"Sodji","year":"2022","journal-title":"Cancer Research Communications"},{"key":"2026031123301574000_14.3.e013290.113","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.21037\/tlcr-23-258","article-title":"Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer","volume":"12","author":"Yuan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2026031123301574000_14.3.e013290.114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis Onc"},{"key":"2026031123301574000_14.3.e013290.115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/0008-5472.CAN-24-4869","article-title":"C5aR1 Inhibition Alleviates Cranial Radiation\u2013Induced Cognitive Decline","volume":"86","author":"Krattli","year":"2026","journal-title":"Cancer Res"},{"key":"2026031123301574000_14.3.e013290.116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002585","article-title":"Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer","volume":"9","author":"Gadwa","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026031123301574000_14.3.e013290.117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1761"},{"key":"2026031123301574000_14.3.e013290.118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"key":"2026031123301574000_14.3.e013290.119","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-139","article-title":"Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo","volume":"9","author":"Hsu","year":"2010","journal-title":"Mol Cancer"},{"key":"2026031123301574000_14.3.e013290.120","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3109\/10428194.2012.681657","article-title":"Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement","volume":"53","author":"Baig","year":"2012","journal-title":"Leukemia & Lymphoma"},{"key":"2026031123301574000_14.3.e013290.121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"2026031123301574000_14.3.e013290.122","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1007\/s00432-022-04459-3","article-title":"Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer","volume":"149","author":"Lordick","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026031123301574000_14.3.e013290.123","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/1535-7163.MCT-22-0723","article-title":"Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103","volume":"22","author":"Bushey","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026031123301574000_14.3.e013290.124","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4049\/jimmunol.2300728","article-title":"Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody","volume":"212","author":"Saxena","year":"2024","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55092-2","article-title":"Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial","volume":"16","author":"Clarke","year":"2025","journal-title":"Nat Commun"},{"key":"2026031123301574000_14.3.e013290.126","doi-asserted-by":"crossref","first-page":"101922","DOI":"10.1016\/j.smim.2024.101922","article-title":"Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches","volume":"77","author":"Ovcinnikovs","year":"2025","journal-title":"Semin Immunol"},{"key":"2026031123301574000_14.3.e013290.127","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.02.011"},{"key":"2026031123301574000_14.3.e013290.128","first-page":"1405","article-title":"Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells","volume":"21","author":"Zhao","year":"2009","journal-title":"Oncol Rep"},{"key":"2026031123301574000_14.3.e013290.129","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3434"},{"key":"2026031123301574000_14.3.e013290.130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751904","article-title":"Herbal NF-\u03baB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis","volume":"11","author":"Ge","year":"2021","journal-title":"Front Oncol"},{"key":"2026031123301574000_14.3.e013290.131","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350820","article-title":"The complement system as a target in cancer immunotherapy","volume":"54","author":"Merle","year":"2024","journal-title":"Eur J Immunol"},{"key":"2026031123301574000_14.3.e013290.132","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4049\/jimmunol.2200952","article-title":"Bispecific Complement Engagers for Targeted Complement Activation","volume":"211","author":"Pedersen","year":"2023","journal-title":"J Immunol"},{"key":"2026031123301574000_14.3.e013290.133","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.185"},{"key":"2026031123301574000_14.3.e013290.134","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063041","article-title":"Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery","volume":"23","author":"Kapoor","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026031123301574000_14.3.e013290.135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1725"},{"key":"2026031123301574000_14.3.e013290.136","doi-asserted-by":"crossref","first-page":"115341","DOI":"10.1016\/j.biopha.2023.115341","article-title":"Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy","volume":"166","author":"Singh","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026031123301574000_14.3.e013290.137","doi-asserted-by":"crossref","unstructured":"Barras D , Ghisoni E , Chiffelle J , et al . Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma . Sci Immunol 2024;9. doi:10.1126\/sciimmunol.adg7995","DOI":"10.1126\/sciimmunol.adg7995"},{"key":"2026031123301574000_14.3.e013290.138","doi-asserted-by":"crossref","first-page":"110217","DOI":"10.1016\/j.celrep.2021.110217","article-title":"Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens","volume":"38","author":"Read","year":"2022","journal-title":"Cell Rep"},{"key":"2026031123301574000_14.3.e013290.139","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.vaccine.2010.08.057","article-title":"Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant","volume":"28","author":"Xu","year":"2010","journal-title":"Vaccine (Auckl)"},{"key":"2026031123301574000_14.3.e013290.140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am J Hematol"},{"key":"2026031123301574000_14.3.e013290.141","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"R\u00f6th","year":"2024","journal-title":"Am J Hematol"},{"key":"2026031123301574000_14.3.e013290.142","doi-asserted-by":"crossref","first-page":"11028","DOI":"10.3390\/ijms252011028","article-title":"Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients","volume":"25","author":"Gavriilaki","year":"2024","journal-title":"IJMS"},{"key":"2026031123301574000_14.3.e013290.143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026031123301574000_14.3.e013290.144","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.05.001"},{"key":"2026031123301574000_14.3.e013290.145","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.49"},{"key":"2026031123301574000_14.3.e013290.146","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004717","article-title":"Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy","volume":"10","author":"Krieg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026031123301574000_14.3.e013290.147","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132162","article-title":"Serum Complement Factor H: A Marker for Progression and Outcome Prediction Towards Immunotherapy in Cutaneous Squamous Cell Carcinoma","volume":"17","author":"Geidel","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026031123301574000_14.3.e013290.148","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-304"},{"key":"2026031123301574000_14.3.e013290.149","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48637-y","article-title":"C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"2026031123301574000_14.3.e013290.150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.553297","article-title":"Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer","volume":"10","author":"Bao","year":"2020","journal-title":"Front Oncol"},{"key":"2026031123301574000_14.3.e013290.151","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1302490","article-title":"Complement factor H: a novel innate immune checkpoint in cancer immunotherapy","volume":"12","author":"Saxena","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026031123301574000_14.3.e013290.152","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1049-y"},{"key":"2026031123301574000_14.3.e013290.153","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.07.019"},{"key":"2026031123301574000_14.3.e013290.154","first-page":"2511","article-title":"Complement factor H or a related protein is a marker for transitional cell cancer of the bladder","volume":"4","author":"Kinders","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2026031123301574000_14.3.e013290.155","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4049\/jimmunol.149.4.1381","article-title":"Expression of complement components of the alternative pathway by glioma cell lines","volume":"149","author":"Gasque","year":"1992","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.156","doi-asserted-by":"crossref","unstructured":"van Essen MF , Peereboom ETM , Schlagwein N , et al . Preferential production and secretion of the complement regulator factor H-like protein 1 (FHL-1) by human myeloid cells. Immunobiology 2023;228. doi:10.1016\/j.imbio.2023.152364","DOI":"10.1016\/j.imbio.2023.152364"},{"key":"2026031123301574000_14.3.e013290.157","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.4049\/jimmunol.1401613","article-title":"Identification of Factor H\u2013like Protein 1 as the Predominant Complement Regulator in Bruch\u2019s Membrane: Implications for Age-Related Macular Degeneration","volume":"193","author":"Clark","year":"2014","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.158","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1392"},{"key":"2026031123301574000_14.3.e013290.159","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/jid.2013.346","article-title":"Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma","volume":"134","author":"Riihil\u00e4","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2026031123301574000_14.3.e013290.160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155522","article-title":"The dual role of complement in cancers, from destroying tumors to promoting tumor development","volume":"143","author":"Lu","year":"2021","journal-title":"Cytokine"},{"key":"2026031123301574000_14.3.e013290.161","doi-asserted-by":"crossref","first-page":"615970","DOI":"10.3389\/fcell.2020.615970","article-title":"A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma","volume":"8","author":"Cai","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026031123301574000_14.3.e013290.162","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.104"},{"key":"2026031123301574000_14.3.e013290.163","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-015-1658-8","article-title":"Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence","volume":"64","author":"Okroj","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2026031123301574000_14.3.e013290.164","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.06.034"},{"key":"2026031123301574000_14.3.e013290.165","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1038\/s41388-019-0739-0","article-title":"CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3","volume":"38","author":"Block","year":"2019","journal-title":"Oncogene"},{"key":"2026031123301574000_14.3.e013290.166","doi-asserted-by":"crossref","first-page":"1519465","DOI":"10.3389\/fimmu.2025.1519465","article-title":"Non-canonical extracellular complement pathways and the complosome paradigm in cancer: a scoping review","volume":"16","author":"de Freitas Oliveira-Tore","year":"2025","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.167","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.06.028"},{"key":"2026031123301574000_14.3.e013290.168","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.18632\/oncotarget.27191","article-title":"Upregulation of C1-inhibitor in pancreatic cancer","volume":"10","author":"Osther","year":"2019","journal-title":"Oncotarget"},{"key":"2026031123301574000_14.3.e013290.169","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2007.07.014"},{"key":"2026031123301574000_14.3.e013290.170","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2174\/1871520616666160201104939","article-title":"Role of Carboxypeptidase N Invasion and Migration in Breast Cancer","volume":"16","author":"Cui","year":"2016","journal-title":"Anticancer Agents Med Chem"},{"key":"2026031123301574000_14.3.e013290.171","doi-asserted-by":"crossref","first-page":"843325","DOI":"10.3389\/fonc.2022.843325","article-title":"Carboxypeptidase N2 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"2026031123301574000_14.3.e013290.172","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04400.x"},{"key":"2026031123301574000_14.3.e013290.173","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ejca.2014.05.005","article-title":"The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack","volume":"50","author":"Kesselring","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026031123301574000_14.3.e013290.174","doi-asserted-by":"crossref","first-page":"215935","DOI":"10.1016\/j.canlet.2022.215935","article-title":"CD55 in cancer: Complementing functions in a non-canonical manner","volume":"551","author":"Bharti","year":"2022","journal-title":"Cancer Lett"},{"key":"2026031123301574000_14.3.e013290.175","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.3390\/cancers16213699","article-title":"Deciphering CD59: Unveiling Its Role in Immune Microenvironment and Prognostic Significance","volume":"16","author":"Patel","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026031123301574000_14.3.e013290.176","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.stemcr.2016.11.008","article-title":"CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance","volume":"8","author":"Chen","year":"2017","journal-title":"Stem Cell Reports"},{"key":"2026031123301574000_14.3.e013290.177","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.12.039"},{"key":"2026031123301574000_14.3.e013290.178","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1104694","article-title":"Intraperitoneal metastasis of ovarian cancer: new insights on resident macrophages in the peritoneal cavity","volume":"14","author":"Miyamoto","year":"2023","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232432","article-title":"The differential role of CR3 (CD11b\/CD18) and CR4 (CD11c\/CD18) in the adherence, migration and podosome formation of human macrophages and dendritic cells under inflammatory conditions","volume":"15","author":"Luk\u00e1csi","year":"2020","journal-title":"PLoS One"},{"key":"2026031123301574000_14.3.e013290.180","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3389\/fimmu.2017.01602","article-title":"Complement Receptor 3 Has Negative Impact on Tumor Surveillance through Suppression of Natural Killer Cell Function","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"2026031123301574000_14.3.e013290.181","doi-asserted-by":"crossref","unstructured":"Vorup-Jensen T , Jensen RK . Structural Immunology of Complement Receptors 3 and 4. Front Immunol 2018;9.","DOI":"10.3389\/fimmu.2018.02716"},{"key":"2026031123301574000_14.3.e013290.182","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350815","article-title":"Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer\u2019s disease","volume":"54","author":"Gedam","year":"2024","journal-title":"Eur J Immunol"},{"key":"2026031123301574000_14.3.e013290.183","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.927977","article-title":"High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels","volume":"27","author":"Yang","year":"2021","journal-title":"Med Sci Monit"},{"key":"2026031123301574000_14.3.e013290.184","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2447406","article-title":"C5a\/C5aR regulates Th1\/Th2 imbalance in sepsis-associated lung injury by promoting neutrophil activation to increase PAD4 expression","volume":"57","author":"Lu","year":"2025","journal-title":"Ann Med"},{"key":"2026031123301574000_14.3.e013290.185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ajpath.2025.02.004","article-title":"C5aR1 Promotes Invasion, Metastasis, and Poor Prognosis in Cutaneous Squamous Cell Carcinoma","volume":"195","author":"Heiskanen","year":"2025","journal-title":"Am J Pathol"},{"key":"2026031123301574000_14.3.e013290.186","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity","volume":"202","author":"Li","year":"2019","journal-title":"The Journal of Immunology"},{"key":"2026031123301574000_14.3.e013290.187","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42146","article-title":"Role of C5aR2 in prognosis of patients with acute respiratory distress syndrome through negative modulation of C5a: A prospective observational study","volume":"11","author":"Rashid","year":"2025","journal-title":"Heliyon"},{"key":"2026031123301574000_14.3.e013290.188","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cai2.29","article-title":"An integrated analysis of C5AR2 related to malignant properties and immune infiltration of gliomas","volume":"1","author":"Huang","year":"2022","journal-title":"Cancer Innov"},{"key":"2026031123301574000_14.3.e013290.189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01074"},{"key":"2026031123301574000_14.3.e013290.190","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5614"},{"key":"2026031123301574000_14.3.e013290.191","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-3083.2009.02329.x","article-title":"Complement receptor 1 (A3650G RsaI and intron 27 HindIII) polymorphisms and risk of gallbladder cancer in north Indian population","volume":"70","author":"Srivastava","year":"2009","journal-title":"Scand J Immunol"},{"key":"2026031123301574000_14.3.e013290.192","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.383"},{"key":"2026031123301574000_14.3.e013290.193","doi-asserted-by":"publisher","DOI":"10.1385\/IR:36:1:197"},{"key":"2026031123301574000_14.3.e013290.194","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29312","article-title":"The causal impact of complement C3d receptor 2 on head and neck cancer microenvironment and its implications for immunotherapy response prediction","volume":"10","author":"Ding","year":"2024","journal-title":"Heliyon"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:30:42Z","timestamp":1773297042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":194,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-013290"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013290","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}